Article Text

Download PDFPDF

720 A phase 1/2 study of BDC-3042, a novel Dectin-2 agonistic antibody, in patients with advanced cancers
  1. Antonio Giordano1,
  2. Ecaterina Dumbrava2,
  3. Aparna R Parikh3,
  4. Justin Kenkel4,
  5. Danlin Cai4,
  6. Damon Demady4,
  7. Lu Xu4,
  8. Michael N Alonso4,
  9. Shelley E Ackerman4,
  10. Edith A Perez4 and
  11. Sharon Wilks5
  1. 1Dana-Farber Cancer Institute, Boston, MA, USA
  2. 2The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  3. 3Mass General Cancer Center, Harvard Medical School Hospital, Charlestown, MA, USA
  4. 4Bolt Biotherapeutics Inc, Redwood City, CA, USA
  5. 5NEXT Oncology, San Antonio, TX, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Tumor-associated macrophages (TAMs) are a major component of the immune infiltrate in most cancers and play a key role in establishing the immunosuppressive tumor microenvironment (TME) that enables tumor progression. However, TAMs are phenotypically plastic and have the potential to be reprogrammed into immunostimulatory cells that enhance innate and adaptive anti-tumor immunity. BDC-3042 is a novel agonistic antibody targeting an immune-activating receptor expressed on TAMs known as Dectin-2 (CLEC6A).1 Dectin-2 is a C-type lectin receptor best known for its role in pathogen recognition and induction of protective immune responses against fungi and other microbes. We have previously demonstrated that Dectin-2 agonism stimulates pro-inflammatory cytokine secretion and antigen presentation by TAMs, resulting in robust CD8+ T cell-mediated anti-tumor immunity in syngeneic mouse models.2 Differential gene expression of Dectin-2 has been found in a wide range of solid tumor-associated macrophages compared to non-malignant tissues. Nonclinical studies with BDC-3042 have demonstrated its potential to reprogram TAMs and elicit anti-tumor activity as a novel immunotherapeutic approach for diverse human cancers.2 A phase 1/2, four-part, first-in-human, dose-escalation and dose-expansion study of BDC-3042 as a single agent and in combination with pembrolizumab in subjects with advanced malignancies has been initiated.

Methods This dose-escalation and dose-expansion study is enrolling approximately 185 subjects with advanced malignancies, including triple-negative breast cancer, renal cell carcinoma, colon cancer, head and neck cancer, non-small cell lung cancer, and ovarian cancer. Primary objectives of the dose-escalation phase are to define safety and tolerability and to determine the recommended phase 2 dose (RP2D) of BDC-3042 as a monotherapy (Part 1) and in combination with pembrolizumab (Part 2). Part 2 is planned to start once single agent BDC-3042 safety data are available. Part 1 will be the dose escalation. The dose-expansion phase of the study will evaluate preliminary anti-tumor activity of BDC-3042 monotherapy (Part 3) and in combination with pembrolizumab (Part 4). Secondary objectives will evaluate pharmacokinetic parameters and pharmacodynamic biomarkers in tumor tissue and in peripheral blood associated with drug exposure. Exploratory analyses will also be conducted to assess BDC-3042’s ability to reprogram TAMs and identify biomarkers associated with BDC-3042 biological activity with and without pembrolizumab. This study is being conducted in the US and is currently recruiting patients.


  1. Kenkel JA, F Xiao, PY Ho, JL Nolin, et al. ‘Abstract 2964: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042.’ Cancer Research 2023;83(7_Supplement):2964.

  2. Kenkel J, P Ho, S Kongara, K Henning, et al. ‘862 Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy.’ Journal for ImmunoTherapy of Cancer 2021;9(Suppl 2):A903-A903.

Ethics Approval Protocols, protocol amendments, and informed consents are approved by Institutional review boards or independent ethics committees of participating sites. The study will be conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice. All patients will provide written informed consent.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.